Stiff and tough bioadhesive patch to limit recurrent disc prolapse
Active Grant Awarded
- Award ID
- R43AR086099
- Recipient
-
Entangl3D, LLC UEI RM8VU3HJGND9
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $314,138
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 21% complete
- Place of performance
- Morrison, CO, USA
Award details come from USAspending.gov.
About this award
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health, awarded Entangl3D, LLC $314,138 under Grant R43AR086099 on September 9, 2026. The award falls under the Arthritis, Musculoskeletal and Skin Diseases Research program (Assistance Listing 93.846), whose NIAMS mission supports research into the causes, treatment, and prevention of these conditions.
The award funds a Phase I SBIR effort to advance DiscPatch, a stiff and tough bioadhesive hydrogel patch that provides mechanical support to the intervertebral disc after discectomy to limit recurrent disc prolapse and herniation. The patch is produced with a patent-pending additive manufacturing method. Phase I work focuses on remaining questions related to DiscPatch design.
Place of performance is Morrison, Colorado. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027. The assistance type is a grant, and the source identifies no sub-recipients.
Description
- Abstract
- The objective of this proposal is to advance discpatch, an innovative stiff and tough bioadhesive patch and a potentially clinically viable solution to prevent recurrent prolapse and herniation of the intervertebral disc after discectomy. Herniated intervertebral discs are a leading cause of lower back pain, and current surgical procedures often fail to prevent RE-herniation because the defect in the disc is left untreated, allowing disc tissue to protrude again through the same weakened area. Given the increasing prevalence of this condition in our aging population, several disc closure devices-including suturing systems, bone-anchored implants, and BIOMATERIALS-have been developed and tested in both pre-clinical and clinical settings. However, these existing approaches face significant limitations, including failure to prevent disc degeneration, uncertain efficacy compared to the standard of care (SUTURES), potential risks of adverse events (bone-anchored implants), and mechanical properties that are inadequate to withstand the challenging disc environment (BIOMATERIALS). To address the limitations of existing solutions, we have designed a stiff and tough bioadhesive hydrogel patch to provide mechanical support to the disc both acutely and long-term. This patch is created using a patent-pending additive manufacturing method that improves material properties. Preliminary validation studies revealed that additive manufacturing can be used to produce hydrogels with disc-like mechanical properties and high-fidelity shapes for designing clinically meaningful tissue patches with strong bioadhesive properties to a variety of wet tissue environments, as would be experienced during spine surgery. Building on these promising advances in BIOMATERIALS and additive manufacturing, this phase I sbir proposal will focus on remaining questions related to discpatch design. Specifically, studies will be targeted at 3D printing porous, highly bioadhesive patches to stabilize the intervertebral disc in EX vivo models (aim 1), and validating that these 3D printed patches are biocompatible, mechanically stable, and integrate with tissue in vitro and in vivo (aim 2). Upon successful completion of these aims, discpatch will be ready for large animal testing in phase II, ultimately paving the way for the commercialization of this technology to address recurrent herniation and alleviate lower back pain for millions of sufferers.
Quick answers
Who received award R43AR086099?
R43AR086099 was awarded to Entangl3D, LLC by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.
How much is award R43AR086099 worth?
$314,138 has been obligated on R43AR086099.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award